TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21737584

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 366
Study: 19936513

Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Yerba mate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 16298235

Group type: EXPERIMENTAL
Intervention: CJD patients with high total tau (t-tau) levels
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CJD patients with low phosphorylated tau at threonine 231 (p-tau231) levels
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Total tau (t-tau) diagnostic accuracy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phosphorylated tau at threonine 231 (p-tau231) diagnostic accuracy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: p-tau231/t-tau ratio diagnostic accuracy
Number of subjects: 3
Study: 14664679

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10757578

Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epidural analgesia and Paracervical block (PCB)
Number of subjects: 44
Study: 8930426

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide three times daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2% pilocarpine four times daily
Number of subjects: 75
Study: 1551720

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g four times a day
Number of subjects: 100

Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 100
Study: 4002788

Group type: COMPARATOR
Intervention: muzolimine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: muzolimine 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: muzolimine 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 30931801

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain placement
Number of subjects: 6858

Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 6858
Study: 28988160

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 511

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 511
Study: 27167763

Group type: EXPERIMENTAL
Intervention: Parental book reading (frequency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head Start program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foster parents in Head Start
Number of subjects: 0
Study: 24904116

Group type: EXPERIMENTAL
Intervention: Treatment regimen B
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Treatment regimen C
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Down syndrome
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Maintenance phase
Number of subjects: 249

Group type: COMPARATOR
Intervention: Overall IRM
Number of subjects: 249
Study: 22407057

Group type: EXPERIMENTAL
Intervention: 3‐h interval clamping (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: non‐clamping (group A)
Number of subjects: 100
Study: 19954777

Group type: EXPERIMENTAL
Intervention: Endurance physical exercise (14 days of cross-country skiing, 12-30km per day, ~10h of activity)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High fat diet (40% of energy derived from fat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low fat diet (30% of energy derived from fat)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance physical exercise
Number of subjects: 20
Study: 18559233

Group type: EXPERIMENTAL
Intervention: Traditional Chinese drug (TCD) treatment with Huzhang Gout Granule and Jinhuang Ointment in acute stage; Yinlian Gout Granule in intermission.
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Western medicine (WM) treatment with diclofenac sodium dual release enteric-coated capsules in acute stage; benzbromarone or allopurinol in intermission.
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Combination of TCD and WM treatment in acute stage and intermission.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment).
Number of subjects: 166
Study: 15612981

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg if body weight >30 kg; 10 mg if <30 kg) given pretransplant and at day 4; Tacrolimus (Tac) administered to obtain blood trough levels of 10-20 ng/ml during the first 2 months and 5-10 ng/ml thereafter; Steroids tapered during the first 6 months and replaced by mycophenolate mofetil (4-600 mg/m² body surface area) depending on previous rejection episodes, infection status, and routine biopsy results.
Number of subjects: 53
Study: 15560817

Group type: EXPERIMENTAL
Intervention: CHX+Zn
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+CPC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+ALC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+NaF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+NO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 10
Study: 11422684

Group type: COMPARATOR
Intervention: Palpation tenderness of masticatory muscles
Number of subjects: 67

Group type: COMPARATOR
Intervention: Combination of palpatory tenderness and clenching habit
Number of subjects: 67

Group type: COMPARATOR
Intervention: Clenching habit alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Negative predictive value of muscle tenderness
Number of subjects: 67
Study: 8996129

Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam (KM): atropine 0.01 mg/kg, midazolam 0.05 mg/kg, ketamine 1.5 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Meperidine-midazolam (MM): meperidine 2 mg/kg, midazolam 0.1 mg/kg
Number of subjects: 22
Study: 7912103

Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 1 microgram/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 2 micrograms/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 3 micrograms/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral mivazerol 800 micrograms
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral mivazerol 1200 micrograms
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral mivazerol 1600 micrograms
Number of subjects: 18
Study: 3520390

Group type: EXPERIMENTAL
Intervention: Aminophylline and clenbuterol combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clenbuterol
Number of subjects: 0
Study: 31910393

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 8 weeks, 7 days per week, twice daily, using POWERbreathe KH1, starting at 50% of maximum inspiratory pressure with progressively increasing load
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 47
Study: 28741729

Group type: EXPERIMENTAL
Intervention: Early hard palate closure (EHPC) at 12 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Late hard palate closure (LHPC) at 36 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (children without CP)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Boys (within UCLP groups)
Number of subjects: 126
Study: 27436668

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 0
Study: 24958577

Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4‐BPT) and methacholine bronchial provocation test (MCh‐BPT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Log10RDR
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: RDR and PD20FEV1 combination
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: RDR (≤ 25th percentile)
Number of subjects: 83
Study: 22677927

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (CNTRL)
Number of subjects: 6
Study: 20546210

Group type: EXPERIMENTAL
Intervention: Sufentanil at ED 20
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Sufentanil at ED 40
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of sufentanil with ropivacaine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (ropivacaine alone)
Number of subjects: 115
Study: 18262758

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate/megestrol acetate plus pharmacologic nutritional support plus L-carnitine plus thalidomide
Number of subjects: 475

Group type: COMPARATOR
Intervention: Pharmacologic nutritional support containing eicosapentaenoic acid
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate/megestrol acetate
Number of subjects: 475
Study: 16874160

Group type: EXPERIMENTAL
Intervention: Serum C3 levels
Number of subjects: 1200
Study: 12791112

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 1.0 ml.kg‐1 body weight (BW) bupivacaine 0.25%
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wound instillation with 0.2 ml.kg‐1 BW bupivacaine 0.5%
Number of subjects: 58
Study: 11020743

Group type: EXPERIMENTAL
Intervention: Neostigmine + Nitroglycerin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (Saline + Placebo)
Number of subjects: 48
Study: 8806245

Group type: EXPERIMENTAL
Intervention: ethamsylate 500 mg six hourly
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: mefenamic acid 500 mg eight hourly
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g six hourly
Number of subjects: 76
Study: 1459517

Group type: EXPERIMENTAL
Intervention: pirenzepine (100 mg/day)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: cimetidine (800 mg/day)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: pirenzepine (75 mg/day)
Number of subjects: 402

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 402
Study: 3901683

Group type: EXPERIMENTAL
Intervention: High dose group (HDG) received 120‐160 mg furosemide daily for six weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Low dose group (LDG) received 20‐40 mg furosemide daily for six weeks
Number of subjects: 83
Study: 30920098

Group type: EXPERIMENTAL
Intervention: Intralesional injection of 0.2 mL of vitamin D3 (300,000 IU) into the base of mother wart for two sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 50
Study: 30179211

Group type: EXPERIMENTAL
Intervention: Vibration (25 Hz)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (sham vibration)
Number of subjects: 36
Study: 27412942

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC), 3 capsules three times daily for 12 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 4 tablets two times daily for 12 weeks
Number of subjects: 56
Study: 25419883

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22611998

Group type: EXPERIMENTAL
Intervention: 100 mg of lidocaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg of lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg vs 200 mg lidocaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 20140830

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diagnostic accuracy studies
Number of subjects: 120
Study: 17565578

Group type: EXPERIMENTAL
Intervention: SRL-ST
Number of subjects: 430

Group type: COMPARATOR
Intervention: SRL-CsA-ST
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 430
Study: 16095507

Group type: EXPERIMENTAL
Intervention: 15 mg/day of 5‐methyl‐tetrahydrofolate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 44
Study: 12466345

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10072746

Group type: EXPERIMENTAL
Intervention: Enhanced program (standard program plus an educational booklet/telephone call)
Number of subjects: 5042

Group type: COMPARATOR
Intervention: Standard program (including rectal examination, fecal occult blood testing, and flexible sigmoidoscopy)
Number of subjects: 5042
Study: 8533868

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (NLA): 7.1 mg droperidol and 0.008 mg/kg body weight fentanyl
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with propofol (IVA): 493.4 mg propofol and 0.004 mg/kg body weight fentanyl
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (BAL): 2.6 mg droperidol and 0.004 mg/kg body weight fentanyl with 0.4 vol.% isoflurane
Number of subjects: 1318
Study: 2148278

Group type: EXPERIMENTAL
Intervention: Enoximone (2 X bolus 0.5 mg/kg; infusion 5.0 micrograms/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine (3.0‐4.0 micrograms/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 7386944

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline-Ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline-Ephedrine-Hydroxyzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31117100

Group type: EXPERIMENTAL
Intervention: Heat-treated Lactobacillus paracasei GM-080
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28527788

Group type: EXPERIMENTAL
Intervention: Game-based inhibition training on a tablet for two months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Game-based inhibition training
Number of subjects: 0
Study: 25893825

Group type: EXPERIMENTAL
Intervention: Short stromal cell telomere lengths (below median)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal-appearing basal cell telomere lengths (short)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Luminal cell telomere lengths (short)
Number of subjects: 82
Study: 23602047

Group type: EXPERIMENTAL
Intervention: Mebeverine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Regul8 with nurse support
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Regul8 with minimal email support
Number of subjects: 135

Group type: COMPARATOR
Intervention: No website
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Regul8 groups
Number of subjects: 135
Study: 21409403

Group type: EXPERIMENTAL
Intervention: Trained
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untrained
Number of subjects: 23
Study: 19727967

Group type: EXPERIMENTAL
Intervention: Concordance score
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Symptomatic score
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Highly concordant co-morbid conditions
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Highly symptomatic conditions
Number of subjects: 1240
Study: 17329193

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 2923

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 2923

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy for SCC
Number of subjects: 2923

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy for adenocarcinoma
Number of subjects: 2923
Study: 15057583

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vertical midline incision
Number of subjects: 28
Study: 11176732

Group type: EXPERIMENTAL
Intervention: Active guideline-based advice exposure
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Passive guideline-based advice exposure
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study: 11096410

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises
Number of subjects: 58

Group type: COMPARATOR
Intervention: Pelvic muscle exercises plus electrical stimulation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: IIQ-7 scores
Number of subjects: 58
Study: 8864327

Group type: COMPARATOR
Intervention: Phenytoin alone (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phenytoin with atovaquone (600 mg phenytoin + 2000 mg atovaquone as two doses of 1000 mg)
Number of subjects: 12
Study: 1824654

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 266

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 266
Study: 6868097

Group type: EXPERIMENTAL
Intervention: Syringe and needle (0.5 ml)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Jet-injector (0.1 ml)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nose drops (0.5 ml)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Bifurcated needle
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Needle planted cylinder
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (24 children)
Number of subjects: 109
Study: 30785053

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 117
Study: 30181436

Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BJ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27687397

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pregabalin 75 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24315404

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 338
Study: 22168752

Group type: EXPERIMENTAL
Intervention: Patients with autoimmune thyroiditis (AT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Euthyroid controls
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Patients with nontoxic multinodular goiter
Number of subjects: 158
Study: 20156896

Group type: EXPERIMENTAL
Intervention: High-fidelity training (HFT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Low-fidelity training (LFT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intervention groups
Number of subjects: 98
Study: 17595001

Group type: EXPERIMENTAL
Intervention: Role Induction (RI)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 353
Study: 16172439

Group type: EXPERIMENTAL
Intervention: Specific program administered by rheumatologists including education, protocol-based clinical management, and administrative duties.
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Standard primary care management with referral to specialized care if needed (control group).
Number of subjects: 1077
Study: 11840224

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg once daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 10067658

Group type: EXPERIMENTAL
Intervention: FM containing Lactobacillus acidophilus L1
Number of subjects: 0
Study: 7742148

Group type: EXPERIMENTAL
Intervention: LTD4
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PGD2
Number of subjects: 20
Study: 2403062

Group type: EXPERIMENTAL
Intervention: 60 mg vitamin A preparation
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A preparation
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Placebo (0 mg vitamin A preparation)
Number of subjects: 2471
Study: 30168905

Group type: EXPERIMENTAL
Intervention: TAK-117 tablet (900 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-117 (600 mg) under fed conditions (high-fat meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAK-117 (900 mg) plus lansoprazole
Number of subjects: 0
Study: 30473033

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (DCC, >5 minutes)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Immediate clamping (ICC, <20 seconds)
Number of subjects: 73
Study: 26681677

Group type: COMPARATOR
Intervention: Placebo (SPCG-6 study)
Number of subjects: 263
Study: 25318563

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (behavioral intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HIV testing and referral for treatment (control)
Number of subjects: 0
Study: 22766124

Group type: EXPERIMENTAL
Intervention: Oral tramadol 50 mg capsules (n = 35)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg tablets (n = 34)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (n = 34)
Number of subjects: 103
Study: 21415811

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion (ACDF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Posterior lumbar decompression surgery
Number of subjects: 38
Study: 17350802

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) 0.59 mg as zinc sulfate with 0.5 mg Fe as ferrous sulfate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) 11.71 mg as zinc sulfate with 10 mg Fe
Number of subjects: 14

Group type: COMPARATOR
Intervention: Iron (Fe) 0.5 mg as ferrous sulfate alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Iron (Fe) 10 mg alone
Number of subjects: 14